ClinicalTrials.gg
CompletedNCT06741683Updated Dec 30, 2025

A Study of Dengue Tetravalent Vaccine (TDV) in Healthy Participants in Japan

A Phase 2/3 interventional study of TDV and Placebo in Dengue Fever, sponsored by Takeda. Completed at 5 sites in Japan. Open to participants aged 4 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-30.

Sponsored by Takeda · Phase 2/3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
187
Allocation
Randomized
Ages
4 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Dengue by Takeda — 2 open to participants now, 5 under way, 3 of them phase 3. Dengue · Takeda.

Enrollment
13th of 15
187 · median 400
Started
2025
with 3 others
Phase 2/3
Only one
of the 17
Registered
15th of 17
by date

Among the 17 studies in Dengue by Takeda, this one is the 13th largest by enrollment of the 15 interventional ones that give a count, is one of 4 that started in 2025, is the only one in phase 2/3, and was the 15th registered.

Dengue

283 studies on the registry are indexed under Dengue; 44 are open to participants now.

Browse Dengue studies →

Open to participants now

2 of the 17 studies in Dengue by Takeda are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 27 Dengue studies recruiting now, 16 (59%) set no upper age limit and 11 (41%) stop at 75 or younger; 16 take children under 18; 9 take healthy volunteers.

This study: 4 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Dengue by Takeda, or all of them as a file.
02

Study summary

Dengue fever is caused by an infection with the dengue virus. Vaccination with TDV can help prevent dengue fever.

The main purpose of this study is to learn about TDV's ability to create an immune response in adults, adolescents, and children administered. In this study, participants will receive 2 vaccinations with TDV (the second 3 months after the first). During the study, participants will visit their study clinic 5 times.

Participants will be in this study for approximately 270 days (9 months).

03

Conditions studied

  • Dengue Fever

Browse trials for

04

Who can participate

Ages eligible
4 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant aged >=4 to less than or equal to (\<=) 60 years at the time of signing the /pediatric assent form.
  2. Participant is Japanese male or female.
  3. Participant is in good health at the time of entry into the trial as determined by medical history, physical examination (including vital signs) and clinical judgment of the investigator.
  4. Participant and/or the participant's legally acceptable representative (LAR) who have signed and dated a written, informed consent/pediatric assent form, and any required privacy authorization prior to the initiation of any trial procedures, and after the nature of the trial has been explained.
  5. Participant can comply with trial procedures and is available for the duration of follow-up.

Exclusion criteria

Exclusion Criteria:

  1. Participant has (s), warning(s), and/or precaution(s) applicable to vaccination with TDV as specified in the Investigator's Brochure.
  2. Participant has a known or allergy to any of the IMP components (including of the IMP).
  3. Participant has behavioral or cognitive impairment or psychiatric disease that, in the opinion of the investigator, may interfere with the participant's ability to participate in the trial.
  4. Participant has a history of progressive or severe neurologic disorder, seizure disorder or neuro-inflammatory disease (example, Guillain-Barré syndrome).
  5. Participant has a active infection (as assessed by the investigator) or body temperature greater than (>) 38.0 degrees Celsius (°C) (>100.4 degrees Fahrenheit [°F]) within 3 days of intended IMP administration on Day 1 (Month [M] 0).

    Note: In principle, oral temperature should be measured for body temperature. In cases where it is difficult to measure oral temperature, such as in young children, underarm (axillary) temperature may be used instead.

  6. Participant has an illness, or history of any illness that, in the opinion of the investigator, might interfere with the results of the trial or pose additional risk to the participant due to involvement in this trial.
  7. Participant has a known or suspected impairment/alteration of immune function, including:

    1. Chronic administration of oral and/or parenteral at doses considered sufficiently (example, >=2 milligram per kilogram [mg/kg] body weight prednisone [or equivalent] for >=14 consecutive days, or >=20 milligram per day [mg/day] prednisone [or equivalent] administered for >=14 consecutive days) within 60 days prior to Day 1 (M0), Note: use of corticosteroids by inhaled, intranasal, intra-articular, bursal, tendon injection, or topical routes is allowed.
    2. Receipt of blood, immunoglobulins, blood products, and/or plasma derivatives within the 90 days prior to Day 1 (M0).
    3. Receipt of immunostimulants within 60 days prior to Day 1 (M0).
    4. Immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within 6 months prior to Day 1 (M0).
    5. Reported or known symptomatic infection or asymptomatic HIV infection when accompanied by evidence of impaired immune function.
    6. Reported or known and/or virus infection.
    7. Genetic immunodeficiency.
  8. Participant has known or suspected abnormalities of splenic or thymic function.
  9. Participant has a known bleeding diathesis, or any condition that may be associated with a prolonged bleeding time.
  10. Participant has a serious chronic or progressive disease deemed to be preclusive to trial entry, that is not medically stable according to the judgment of the investigator.
  11. Participant is participating in any clinical trial with another product within 30 days prior to Day 1 (M0) or plans to participate in another clinical trial at any time during the conduct of this trial.
  12. Participant has previously received a vaccination against flavivirus other than Japanese encephalitis (JE) (investigational or licensed).
  13. Participant who received any other vaccines within 14 days (for inactivated vaccines) or 28 days (for ) prior to Day 1 (M0) or who are planning to receive any vaccine other than IMP within 28 days of IMP administration.
  14. Participant who received a coronavirus vaccine within 14 days prior to Day 1 (M0).
  15. Participant who received a vaccine authorized for emergency use within 28 days prior to Day 1 (M0).
  16. Participant who received any JE vaccines within 28 days prior to Day 1 (M0) or who are planning to receive any JE vaccines during the trial period.
  17. Previous participation in any clinical trial of a dengue or other flavivirus candidate vaccine, except for participants who received placebo in those trials.
  18. Participant with (BMI) >=35 kilograms per square meter (kg/m\^2) on Day 1 (M0).
  19. Participant who intends to travel to dengue endemic areas during the trial period.
  20. Participant with documented or suspected disease caused by a flavivirus and participants with a history of prolonged (>=1 year) habitation in a dengue endemic area.
  21. Participant with history of substance or alcohol abuse within the past 2 years prior to Day 1 (M0).
  22. Female participants who are pregnant (that is, a positive or indeterminate pregnancy test) or breastfeeding.
  23. Females of who are sexually active and who have not used any of the acceptable methods for at least 2 months prior to Day 1 (M0).

    1. "Childbearing potential" is defined as status post onset of menarche and not meeting any of the following conditions: menopausal for at least 2 years, status after bilateral tubal ligation for at least 1 year, status after bilateral oophorectomy, or status after hysterectomy.
    2. Acceptable contraceptive methods" are defined as one or more of the following:

      • Hormonal contraceptive.
      • Barrier method (condom or diaphragm) every time during intercourse.
      • Intrauterine device.
      • Monogamous relationship with a vasectomized partner. The partner must have been vasectomized for at least 6 months prior to the participant's trial enrollment.
  24. Females of "childbearing potential" or non-sterilized males, who refuse to use an "acceptable contraceptive method" up to 6 weeks post second IMP administration on Day 90 (M3). In addition, they must be advised not to donate ova or sperm during this period.
  25. A first degree relative is involved in the conduct of this trial.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
187 participants (actual)

Study arms

  • Experimental
    Cohort 1: TDV 0.5 mL

    Participants with the age group 18 to 60 years will receive TDV, 0.5 milliliter (mL) subcutaneous (SC) injections, on Day 1 and Day 90.

    Biological: TDV

  • Placebo comparator
    Cohort 1: Placebo

    Participants with the age group 18 to 60 years will receive placebo (normal saline), 0.5 mL SC injections, on Day 1 and Day 90.

    Other: Placebo

  • Experimental
    Cohort 2: TDV 0.5 mL

    Participants with the age group 4 to 17 years will receive TDV, 0.5 mL SC injections, on Day 1 and Day 90.

    Biological: TDV

Interventions

  • BiologicalTDV

    TDV SC injection.

    Also known as: TAK-003

  • OtherPlacebo

    Placebo SC injection.

    Also known as: Placebo SC injection.

06

What researchers measure

Primary outcomes

  1. Percentage of Seropositive Participants for Each of the 4 Dengue Virus Serotypes on Day 120

    Seropositivity is defined as a reciprocal neutralizing titer greater than or equal to (\>=) 10. The 4 dengue virus serotypes (DENV) are DENV-1, DENV-2, DENV-3 and DENV-4.

    Time frame: Day 120

Secondary outcomes

  1. Percentage of Seropositive Participants for Each of the 4 Dengue Virus Serotypes on Day 1, Day 30, Day 90 and Day 270

    Seropositivity is defined as a reciprocal neutralizing titer \>=10. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4.

    Time frame: Day 1, Day 30, Day 90 and Day 270

  2. Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the 4 Dengue Virus Serotypes on Day 1, Day 30, Day 90, Day 120 and Day 270

    GMTs of neutralizing antibodies will be measured by microneutralization Test (MNT) for each of the 4 Dengue serotypes. The 4 dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4.

    Time frame: Day 1, Day 30, Day 90, Day 120 and Day 270

  3. Percentage of Seropositive Participants for Multiple (2, 3, or 4) Dengue Serotypes on Day 1, Day 30, Day 90, Day 120 and Day 270

    Seropositivity is defined as a reciprocal neutralizing titer \>=10 for multiple dengue serotypes (2, 3, or 4).

    Time frame: Day 1, Day 30, Day 90, Day 120 and Day 270

  4. Number of Participants With Solicited Local (Injection Site) Adverse Events (AEs) for 7 days After Vaccination at Day 1 and Day 90

    The solicited local (at injection site) AEs includes pain, erythema, and swelling.

    Time frame: For 7 days after vaccination at Day 1 and Day 90

  5. Number of Participants with Solicited Local (Injection Site) AEs by Severity for 7 days After Vaccination at Day 1 and Day 90

    The solicited local (at injection site) AEs includes pain, erythema, and swelling. The AEs will be graded by investigator as Grade 0: none, Grade 1: mild, Grade 2: moderate and Grade 3: severe.

    Time frame: For 7 days after vaccination at Day 1 and Day 90

  6. Number of Participants With Solicited Systemic AEs for 14 days After Vaccination at Day 1 and Day 90

    The solicited systemic AEs for less than (\<) 6 years of age will be fever, irritability/fussiness, drowsiness, and loss of appetite; and for \>=6 years of age will be asthenia, fever, headache, malaise, and myalgia.

    Time frame: For 14 days after vaccination at Day 1 and Day 90

  7. Number of Participants With Solicited Systemic AEs by Severity for 14 days After Vaccination at Day 1 and Day 90

    The solicited systemic AEs for \<6 years of age will be fever, irritability/fussiness, drowsiness, and loss of appetite; and for \>=6 years of age will be asthenia, fever, headache, malaise, and myalgia. The AEs will be graded by investigator as Grade 0: none, Grade 1: mild, Grade 2: moderate and Grade 3: severe.

    Time frame: For 14 days after vaccination at Day 1 and Day 90

  8. Percentage of Participants With Any Unsolicited AEs for 28 days After Vaccination at Day 1 and Day 90

    An unsolicited AE is any AE reported by the participant that is not specified as a solicited AE or is specified as a solicited AE but starts outside the period for reporting a solicited AE (that is, 7 days and 14 days in total including the day of Investigational Medicinal Product \[IMP\] administration).

    Time frame: For 28 days after vaccination at Day 1 and Day 90

  9. Percentage of Participants With Serious Adverse Event (SAE)

    A SAE is defined as any untoward medical occurrence that: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/ incapacity, leads to a congenital anomaly/birth defect in the offspring of a participant, is an important medical event.

    Time frame: From first vaccination on Day 1 through the end of trial (up to Day 270)

  10. Percentage of Participants With Medically Attended AEs (MAAEs)

    MAAEs are defined as AEs leading to an unscheduled visit or by a healthcare professional including visits to an emergency department (medically attended visits), but not fulfilling seriousness criteria.

    Time frame: From first vaccination on Day 1 through the end of trial (up to Day 270)

07

Study locations

5 sites
  • PS Clinic
    Fukuoka, Fukuoka, Japan
  • Saitama City Hospital
    Saitama-shi, Saitama, Japan
  • Sumida Hospital
    Sumida-ku, Tokyo, Japan
  • OKURA Otolaryngology Clinic
    Toshima-ku, Tokyo, Japan
  • Tamura Clinic
    Tokyo, Japan
08

References and documents

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2025 to primary completion in Jul 2025, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2024
First posted
Dec 19, 2024
StartActual
Jan 31, 2025
Primary completionActual
Jul 9, 2025
CompletionActual
Dec 17, 2025
Last update
Dec 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06741683
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Dec 19, 2024
Start date
Jan 31, 2025
Primary completion
Jul 9, 2025
Completion
Dec 17, 2025
Last update
Dec 30, 2025

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion